Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D

被引：0
|
作者：
Yale, Jean-Francois
Major-Pedersen, Atheline
Catarig, Andrei-Mircea
Jain, Rashmi
Menzen, Markus
Holmes, Patrick
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-797-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
797-P
引用
收藏
页数：3
相关论文
共 50 条
  • [21] GLP-1-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting (EXPERT Study)
    Lingvay, Ildiko
    Kirk, Andreas Ross
    Lophaven, Soren
    Wolden, Michael L.
    Shubrook, Jay H.
    DIABETES, 2020, 69
  • [22] Efficacy and Safety in Chinese T2D Patients Discontinued from OAM to Once-Weekly Dulaglutide Monotherapy
    Li, Yanbing
    Zhang, Bin
    Liu, Siying
    DIABETES, 2020, 69
  • [23] Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study
    Napoli, Raffaele
    Berra, Cesare
    Catarig, Andrei-Mircea
    Di Loreto, Chiara
    Donatiello, Emily
    Berentzen, Tina Landsvig
    Pitocco, Dario
    Giorgino, Francesco
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1658 - 1667
  • [24] Real-World Impact of Once-Weekly Injectable Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-OW Injectable Semaglutide)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Tan, Xi
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Chen, Justin
    King, Aaron A.
    DIABETES, 2023, 72
  • [25] Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study
    Shi, Chenyang
    Tan, Yijiong
    Hu, Shanshan
    Qin, Yingyi
    Tang, Yuanjun
    Wang, Yufan
    Fan, Guorong
    DIABETES OBESITY & METABOLISM, 2024, 26 (06): : 2513 - 2516
  • [26] Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes
    Vilsboll, Tina
    Lindahl, Caroline O.
    Nielsen, Nick F.
    Tikkanen, Christian K.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1740 - 1749
  • [27] Patients reaching treatment targets with once-weekly semaglutide in real-world practice: pooled analysis of four SURE studies
    Rudofsky, G.
    Bodholdt, U.
    Catarig, A. -M.
    Ekberg, N. Rajamand
    Erhan, U.
    Liutkus, J. F.
    Tariq, M.
    Holmes, P.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 230 - 231
  • [28] Mobile health application as a real-world data resource: self-recorded weight reduction with once-weekly semaglutide
    Bodholdt, U.
    Birot, S.
    Catarig, A. -M.
    Erhan, U.
    Knop, F. K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 232 - 233
  • [29] Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data
    Horii, Takeshi
    Masudo, Chikako
    Takayanagi, Yui
    Oikawa, Yoichi
    Shimada, Akira
    Mihara, Kiyoshi
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (11) : 1578 - 1584
  • [30] Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies
    Yale, J. -F.
    Catarig, A. -M.
    Catrina, S. -B.
    Erhan, U.
    Sathyapalan, T.
    Schultes, B.
    Tariq, M.
    Knudsen, S. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 230 - 230
12345